<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01120028</url>
  </required_header>
  <id_info>
    <org_study_id>CTSU3C1</org_study_id>
    <secondary_id>2008-008553-27</secondary_id>
    <secondary_id>ISRCTN88894088</secondary_id>
    <nct_id>NCT01120028</nct_id>
  </id_info>
  <brief_title>Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy</brief_title>
  <acronym>3C</acronym>
  <official_title>Open-label, Randomised Multicentre Study of CAMPATH-1H Versus Basiliximab Induction Treatment and Sirolimus Versus Tacrolimus Maintenance Treatment for the Preservation of Renal Function in Patients Receiving Kidney Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health Service, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 3C study will investigate whether reducing exposure to calcineurin inhibitors (by using
      more potent antibody induction treatment and/or an elective switch to sirolimus) can improve
      the function and survival of kidney transplants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-term survival of kidney transplants has not improved over the past decade despite
      reductions in the rate of acute rejection. The commonest cause of late graft loss is chronic
      allograft nephropathy which is frequently caused by calcineurin inhibitor toxicity.
      Therefore, it may be possible to improve long-term graft outcomes by reducing the amount of
      calcineurin inhibitor exposure.

      Two possible strategies to do this will be tested. Firstly, Campath-1H (a monoclonal
      lymphocyte-depleting antibody) will be compared to standard basiliximab-based induction. All
      patients will then receive tacrolimus-based maintenance therapy for 6 months (using lower
      doses in the Campath-1H arm).

      At six months, patients will be re-randomised between remaining on tacrolimus and converting
      to sirolimus (and therefore no longer take calcineurin inhibitors). Patients will then be
      followed-up in clinic and through routine NHS registries to collect information on relevant
      outcomes (including graft function, survival, hospitalisations and death).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biopsy-proven acute rejection</measure>
    <time_frame>6 months</time_frame>
    <description>Primary outcome for induction therapy comparison</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft function</measure>
    <time_frame>2 and 5 years post-transplantation</time_frame>
    <description>Primary outcome for maintenance therapy comparison</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft survival</measure>
    <time_frame>6 months, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious infection</measure>
    <time_frame>2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignancy</measure>
    <time_frame>2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major vascular event</measure>
    <time_frame>2 and 5 years</time_frame>
    <description>Composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular death or arterial revascularization</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Campath-1H/Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy allocation: Campath-1H Maintenance therapy allocation (at 6 months post-transplant): Sirolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Campath-1H/Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy allocation: Campath-1H Maintenance therapy allocation (at 6 months post-transplant): Tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basliximab/Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy allocation: Basiliximab Maintenance therapy allocation (at 6 months post-transplant): Tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basliximab/Sirolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy allocation: Basiliximab Maintenance therapy allocation (at 6 months post-transplant): Sirolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Alemtuzumab 30 mg intravenously or subcutaneously Two doses 24 hours apart</description>
    <arm_group_label>Campath-1H/Sirolimus</arm_group_label>
    <arm_group_label>Campath-1H/Tacrolimus</arm_group_label>
    <other_name>Campath-1H</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>20 mg intravenously Two doses 96 hours apart</description>
    <arm_group_label>Basliximab/Tacrolimus</arm_group_label>
    <arm_group_label>Basliximab/Sirolimus</arm_group_label>
    <other_name>Simulect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus: target trough levels 5-10 ng/mL for first 6 months, then 5-8 ng/mL</description>
    <arm_group_label>Campath-1H/Sirolimus</arm_group_label>
    <arm_group_label>Basliximab/Sirolimus</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Target trough level 5-12 ng/mL for first 6 months after basiliximab; 5-7 ng/mL for first six months after basiliximab. 5-7 ng/mL for all participants after 6 months.</description>
    <arm_group_label>Campath-1H/Tacrolimus</arm_group_label>
    <arm_group_label>Basliximab/Tacrolimus</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men or women aged over 18 years

          -  recipient of kidney transplant (planned in next 24 hours)

        Exclusion Criteria:

          -  recipients of multi-organ transplant

          -  previous treatment with Campath-1H

          -  active infection (including HIV, hepatitis B or C)

          -  history of anaphylaxis to humanized monoclonal antibody

          -  history of malignancy (except adequately treated non-melanoma skin cancer)

          -  loss of kidney transplant within 6 months not due to technical reasons

          -  medical history that might limit the individual's ability to take trial treatments for
             the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Friend</last_name>
    <role>Study Director</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Colin Baigent</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin J Landray</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Harden</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Haynes</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxon</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry &amp; Warwickshire</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull and East Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool and Broadgreen University Hospitals NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bart's and the London NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas's NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hampstead NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester NHS Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle-upon-Tyne Hospitals NHS Trust</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plymouth Teaching Hospitals NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospitals NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Trust</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2010</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

